Pancreatobiliary Carcinoma — Trials

Pancreatobiliary Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

2,128 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 698
Recruiting: 403
Ph III recruiting: 36
Growth YoY: +22%
Industry share: 30%
Top sponsor: National Cancer Institute (NCI)
Termination share: 37%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (303)

clinicaltrialsPublishedShowing 1–3 of 3 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04566393	Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies	available	—	—	xCuresINDUSTRY	1	Jun 4, 2026	clinicaltrials
NCT07612930	Expanded Access to PCNAT-01 for Patients With Resected Pancreatic Ductal Adenocarcinoma Following Surgical Resection and Adjuvant Therapy	available	—	—	Anda Biopharmaceutical Development (Shenzhen) Co., Ltd.INDUSTRY	0	May 29, 2026